10 months ago

SeQuent-Viyash Merger Approved by NCLT

SeQuent-Viyash Merger Approved by NCLT
NCLT greenlights SeQuent Scientific - Viyash Lifesciences merger · thehindubusinessline.com

Two big companies, SeQuent Scientific and Viyash Lifesciences, have been allowed to join together by a special court.

This will make them the biggest company in India that takes care of animal health.

They will work on medicines for pets and other animals, and also make medicines for other companies.

The new company will be very strong and have a lot of money.

Key facts

Revenue (H1 FY2026)
₹1,650 crore
EBITDA (H1 FY2026)
₹320 crore
Net Debt to EBITDA Ratio
0.7 times
Focus Areas
Pet health, bone & joint disease, dermatitis, diabetes, cardiology, oncology
Stock Performance
SeQuent Scientific shares down marginally at ₹250

Quotes

Dr. Haribabu Bodepudi, Founder and CEO, Viyash Lifesciences

Dr. Haribabu Bodepudi is the founder and CEO of Viyash Lifesciences, an integrated global pharmaceutical company.

“With the strength in R&D, custom development capabilities, manufacturing capacities and a streamlined supply chain, the company would emerge as an innovative and reliable partner for customers across the world.”
thehindubusinessline.com

Rajaram Narayanan, Managing Director and CEO, SeQuent Scientific

Rajaram Narayanan is the managing director and CEO of SeQuent Scientific, a leading player in the global animal health industry.

“With this merger, the company will be uniquely positioned to build a modern business and deliver on the requirements of pet owners, farmers and animal health professionals. The merged entity will set new benchmarks in quality, innovation and customer trust.”
thehindubusinessline.com

Sources

Related news